The Food and Drug Administration (FDA) and the Central Ethics Committee in the United States have accepted Xbranes IND application for initiation of the Xplore trial, a phase III trial with Xlucane, a ranibizumab (Lucentis®) biosimilar candidate.

“It is with great satisfaction we can announce acceptance from the FDA and the Central Ethics Committee to initiate the Xplore trial. Applications to the additional countries are being submitted continuously during January and February. First patient in is...

Innovent Announces First Patient Dosed in a Phase III Clinical Trial of Anti-PD-1 Antibody Tyvyt® (Sintilimab injection) as First-line Treatment for Patients with Advanced Gastric Cancer

Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines, announced today that the first patient has been dosed in a phase III clinical trial (ORIENT-16) that is to evaluate...

Access to Care, Knowledge About Genetic Testing and Clinical Trials Identified as Key Issues in Landmark Survey of Neuromuscular Community

ONEVoice, a landmark survey funded by the Muscular Dystrophy Association (MDA) and conducted by Edge Research, has identified key areas of concern among more than 3,000 respondents – 2,430 adults with neuromuscular disease and 932 caregivers/family members – as well...
SEARCH FOR STUDIES